Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swedish Orphan Biovitrum AB

www.sobi.com

Latest From Swedish Orphan Biovitrum AB

REMS Abuse Website: Has It Changed The Behavior Of Innovators?

Updated numbers from the US FDA's REMS abuse website show that Celgene has received two additional safety determination letters, raising question's about whether the public list has changed the practices of brand companies hindering generic company access to samples.
Generic Drugs Risk Management

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Profitable Pharming Expands Ruconest Potential And Resurrects Pompe Pipeline

Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.

Rare Diseases Companies

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Sobi
  • Biovitrum AB
  • Swedish Orphan Biovitrum
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Swedish Orphan Biovitrum AB
  • Senior Management
  • Guido Oelkers, PhD, CEO
    Henrik Stenqvist, CFO
    Milan Zdravkovic, MD, PhD, Head, R&D & CMO
  • Contact Info
  • Swedish Orphan Biovitrum AB
    Phone: (46) 8 697 20 00
    Tomtebodavägen 23A
    Stockholm, SE-112 76
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register